<p>Alpha Tau Medical Ltd.（納斯達克代碼：DRTS - 獲取免費報告）在週一的交易中股價創下 52 周新高。該股最高交易價格為 9.90 美元，最後交易價格為 9.9750 美元，成交量為 1,997,160 股。該股此前收盤價為 8.51 美元。</p>
<p>獲取 <strong>Alpha Tau Medical</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>幾家研究公司對 DRTS 進行了評論。Piper Sandler 在 3 月 4 日的研究報告中重申了對 Alpha Tau Medical 的 “中性” 評級，並設定了 5.00 美元的目標價。HC Wainwright 在 3 月 10 日的研究報告中重申了對 Alpha Tau Medical 的 “買入” 評級，並設定了 12.00 美元的目標價。花旗集團在 3 月 11 日的研究報告中將 Alpha Tau Medical 的目標價從 7.00 美元上調至 9.00 美元，並給予該公司 “買入” 評級。Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Alpha Tau Medical 的 “賣出（d-）” 評級。最後，Zacks Research 在 2 月 17 日的研究報告中將 Alpha Tau Medical 的評級從 “強烈賣出” 上調至 “持有”。兩位股票研究分析師給予該股 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Alpha Tau Medical 目前的共識評級為 “持有”，平均目標價為 8.67 美元。</p>
<p><strong>查看我們對 Alpha Tau Medical 的最新分析</strong></p>
<h2>Alpha Tau Medical 股價上漲 19.8%</h2>
<p>該公司 50 日簡單移動平均線為 7.38 美元，200 日簡單移動平均線為 6.10 美元。該股市值為 8.9735 億美元，市盈率為-19.28，貝塔值為 1.11。該公司的債務與股本比率為 0.08，速動比率為 7.45，流動比率為 7.45。</p>
<p>Alpha Tau Medical（納斯達克代碼：DRTS - 獲取免費報告）最近在 3 月 9 日公佈了其財報。該公司報告季度每股收益為（0.14 美元），低於分析師共識預期的（0.13 美元）0.01 美元。整體來看，股票分析師預計 Alpha Tau Medical Ltd.在本年度將發佈-0.5 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>幾家大型投資者最近對該公司的持倉進行了調整。Mariner LLC 在第四季度將其在 Alpha Tau Medical 的持倉增加了 1.6%。Mariner LLC 目前擁有 125,165 股該公司的股票，價值 620,000 美元，此前在該期間又購買了 1,915 股。Trifecta Capital Advisors LLC 在第四季度購買了 Alpha Tau Medical 的新頭寸，價值 48,000 美元。Levin Capital Strategies L.P.在第三季度將其在 Alpha Tau Medical 的持倉增加了 6.3%。Levin Capital Strategies L.P.目前擁有 204,714 股該公司的股票，價值 923,000 美元，此前在該期間又購買了 12,200 股。Envestnet Asset Management Inc.在第三季度購買了 Alpha Tau Medical 的新頭寸，價值 62,000 美元。最後，Wells Fargo &amp; Company MN 在第四季度將其在 Alpha Tau Medical 的持倉增加了 291.7%。Wells Fargo &amp; Company MN 目前擁有 23,500 股該公司的股票，價值 116,000 美元，此前在該期間又購買了 17,500 股。2.65% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Alpha Tau Medical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Alpha Tau Medical Ltd.是一家總部位於以色列內斯齊奧納的醫療技術公司，專注於開發針對實體腫瘤的靶向α輻射療法。該公司的核心創新，稱為擴散α發射體輻射療法（DaRT），利用短壽命放射性同位素將高能α粒子直接輸送到腫瘤組織內或相鄰區域。通過利用α輻射的強大細胞毒性效應，Alpha Tau Medical 旨在提供一種新穎的近距離放射治療方法，可能克服放射抗性並保護周圍健康組織。</p>
<p>該公司的主打產品 Alpha DaRT 目前正在臨牀研究中評估，適用於複發性或轉移性頭頸癌、皮膚癌和其他實體腫瘤等多種適應症。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Alpha Tau Medical</li>
<li>MercadoLibre 大膽投資增長：折扣加深</li>
<li>AI 分紅增加：三隻巨頭股票提升分紅</li>
<li>瘋狂的 Monday.com：這家 SaaS 領軍企業的反彈只是開始</li>
<li>5 只有望受益於 AI 推理熱潮的股票</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Alpha Tau Medical 嗎？</h2>
<p>在考慮投資 Alpha Tau Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Alpha Tau Medical 並不在名單上。</p>
<p>雖然 Alpha Tau Medical 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DRTS

<p>Alpha Tau Medical (NASDAQ:DRTS) 的股票達到新的 52 周高點 9.90 美元，收盤價為 9.9750 美元，交易量為 1,997,160 股。分析師的評級各不相同：Piper Sandler 維持 “中性” 評級，目標價為 5.00 美元，而 HC Wainwright 則給予 “買入” 評級，目標價為 12.00 美元。該公司的市值為 8.9735 億美元，市盈率為-19.28。公司專注於針對實體腫瘤的靶向α輻射療法，其主要產品 Alpha DaRT 正在進行多種癌症的臨牀研究</p>

<p>Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $9.90 and last traded at $9.9750, with a volume of 1997160 shares changing hands. The stock had previously closed at $8.51.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd.（納斯達克代碼：DRTS - 獲取免費報告）在週一的交易中股價創下 52 周新高。該股最高交易價格為 9.90 美元，最後交易價格為 9.9750 美元，成交量為 1,997,160 股。該股此前收盤價為 8.51 美元。</p>
</div><p>Get <strong>Alpha Tau Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Alpha Tau Medical</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several research firms have commented on DRTS. Piper Sandler reaffirmed a &#34;neutral&#34; rating and set a $5.00 price objective on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $12.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, March 10th. Citigroup upped their price objective on Alpha Tau Medical from $7.00 to $9.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Finally, Zacks Research upgraded Alpha Tau Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Alpha Tau Medical presently has a consensus rating of &#34;Hold&#34; and an average target price of $8.67.</p>
<div class="lb-trans"><p>幾家研究公司對 DRTS 進行了評論。Piper Sandler 在 3 月 4 日的研究報告中重申了對 Alpha Tau Medical 的 “中性” 評級，並設定了 5.00 美元的目標價。HC Wainwright 在 3 月 10 日的研究報告中重申了對 Alpha Tau Medical 的 “買入” 評級，並設定了 12.00 美元的目標價。花旗集團在 3 月 11 日的研究報告中將 Alpha Tau Medical 的目標價從 7.00 美元上調至 9.00 美元，並給予該公司 “買入” 評級。Weiss Ratings 在 4 月 20 日的研究報告中重申了對 Alpha Tau Medical 的 “賣出（d-）” 評級。最後，Zacks Research 在 2 月 17 日的研究報告中將 Alpha Tau Medical 的評級從 “強烈賣出” 上調至 “持有”。兩位股票研究分析師給予該股 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Alpha Tau Medical 目前的共識評級為 “持有”，平均目標價為 8.67 美元。</p>
</div><p><strong>View Our Latest Analysis on Alpha Tau Medical</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Alpha Tau Medical 的最新分析</strong></p>
</div><h2>Alpha Tau Medical Trading Up 19.8%</h2>
<div class="lb-trans"><h2>Alpha Tau Medical 股價上漲 19.8%</h2>
</div><p>The business has a fifty day simple moving average of $7.38 and a 200 day simple moving average of $6.10. The stock has a market cap of $897.35 million, a price-to-earnings ratio of -19.28 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45.</p>
<div class="lb-trans"><p>該公司 50 日簡單移動平均線為 7.38 美元，200 日簡單移動平均線為 6.10 美元。該股市值為 8.9735 億美元，市盈率為-19.28，貝塔值為 1.11。該公司的債務與股本比率為 0.08，速動比率為 7.45，流動比率為 7.45。</p>
</div><p>Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its earnings results on Monday, March 9th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, equities analysts anticipate that Alpha Tau Medical Ltd. will post -0.5 EPS for the current year.</p>
<div class="lb-trans"><p>Alpha Tau Medical（納斯達克代碼：DRTS - 獲取免費報告）最近在 3 月 9 日公佈了其財報。該公司報告季度每股收益為（0.14 美元），低於分析師共識預期的（0.13 美元）0.01 美元。整體來看，股票分析師預計 Alpha Tau Medical Ltd.在本年度將發佈-0.5 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several large investors have recently made changes to their positions in the company. Mariner LLC raised its position in shares of Alpha Tau Medical by 1.6% in the 4th quarter. Mariner LLC now owns 125,165 shares of the company's stock worth $620,000 after buying an additional 1,915 shares during the period. Trifecta Capital Advisors LLC purchased a new position in shares of Alpha Tau Medical in the 4th quarter worth $48,000. Levin Capital Strategies L.P. raised its position in shares of Alpha Tau Medical by 6.3% in the 3rd quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company's stock worth $923,000 after buying an additional 12,200 shares during the period. Envestnet Asset Management Inc. purchased a new position in shares of Alpha Tau Medical in the 3rd quarter worth $62,000. Finally, Wells Fargo &amp; Company MN raised its position in shares of Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo &amp; Company MN now owns 23,500 shares of the company's stock worth $116,000 after buying an additional 17,500 shares during the period. 2.65% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家大型投資者最近對該公司的持倉進行了調整。Mariner LLC 在第四季度將其在 Alpha Tau Medical 的持倉增加了 1.6%。Mariner LLC 目前擁有 125,165 股該公司的股票，價值 620,000 美元，此前在該期間又購買了 1,915 股。Trifecta Capital Advisors LLC 在第四季度購買了 Alpha Tau Medical 的新頭寸，價值 48,000 美元。Levin Capital Strategies L.P.在第三季度將其在 Alpha Tau Medical 的持倉增加了 6.3%。Levin Capital Strategies L.P.目前擁有 204,714 股該公司的股票，價值 923,000 美元，此前在該期間又購買了 12,200 股。Envestnet Asset Management Inc.在第三季度購買了 Alpha Tau Medical 的新頭寸，價值 62,000 美元。最後，Wells Fargo &amp; Company MN 在第四季度將其在 Alpha Tau Medical 的持倉增加了 291.7%。Wells Fargo &amp; Company MN 目前擁有 23,500 股該公司的股票，價值 116,000 美元，此前在該期間又購買了 17,500 股。2.65% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Alpha Tau Medical Company Profile</h2>
<div class="lb-trans"><h2>Alpha Tau Medical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd.是一家總部位於以色列內斯齊奧納的醫療技術公司，專注於開發針對實體腫瘤的靶向α輻射療法。該公司的核心創新，稱為擴散α發射體輻射療法（DaRT），利用短壽命放射性同位素將高能α粒子直接輸送到腫瘤組織內或相鄰區域。通過利用α輻射的強大細胞毒性效應，Alpha Tau Medical 旨在提供一種新穎的近距離放射治療方法，可能克服放射抗性並保護周圍健康組織。</p>
</div><p>The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.</p>
<div class="lb-trans"><p>該公司的主打產品 Alpha DaRT 目前正在臨牀研究中評估，適用於複發性或轉移性頭頸癌、皮膚癌和其他實體腫瘤等多種適應症。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Alpha Tau Medical</li>
<li>MercadoLibre Boldly Invests in Growth: Discount Deepens</li>
<li>AI Dividend Increases: 3 Massive Winners Boosting Payouts</li>
<li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li>
<li>5 Stocks Positioned to Benefit From the AI Inference Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Alpha Tau Medical</li>
<li>MercadoLibre 大膽投資增長：折扣加深</li>
<li>AI 分紅增加：三隻巨頭股票提升分紅</li>
<li>瘋狂的 Monday.com：這家 SaaS 領軍企業的反彈只是開始</li>
<li>5 只有望受益於 AI 推理熱潮的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alpha Tau Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Alpha Tau Medical 嗎？</h2>
</div><p>Before you consider Alpha Tau Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Alpha Tau Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Alpha Tau Medical 並不在名單上。</p>
</div><p>While Alpha Tau Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Alpha Tau Medical 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Alpha Tau Medical (NASDAQ:DRTS) Sets New 52-Week High  - Time to Buy?

Market Beat

Alpha Tau Medical

Piper Sandler Cos

Alliance HC

REPUBLIC HC

Hancock Whitney

Nano Labs

花旗

Weis Markets

卡爾蔡司

NEUBERGER BERMAN REAL ES-W/I

Zacks Quality International ETF

Zacks Focus Growth ETF

Zacks Small/Mid Cap ETF

Gulf Marine Services PLC

Vision Marine Tech

RanMarine Technology B.V.

Logan Capital Broad Inno Growth ETF

Trinity Capital

Brown Advisory US Smaller Companies PLC GBP

Levi Strauss

Atom Livin Tech Co., Ltd.

Sun Capital Management Corp.

Eneti

Enovix

Investar控股

富國銀行

拉美商業服務

美國股票 MarketBeta ETF - Goldman Sachs

GS MarketBeta Intl Equity ETF

MarketWise

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Hancock Whitney Pref Share HWCPZ 6.25 06/15/60

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Trinity Capital Pref Share TRINL 7 01/16/25

TRINITY CAPITAL INC 7.875% NTS 30/09/2029

TRINITY CAPITAL INC 7.875% NOTES DUE 2029

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Alpha Tau Medical（NASDAQ:DRTS）創下 52 周新高 - 現在是買入的好時機嗎？